Alachua Biotech Startup Synvitta Aims to Revolutionize Medical Diagnostics

New leadership partnership and advanced testing platform promise faster, more precise and accessible healthcare solutions.

Apr. 17, 2026 at 1:05am

Got story updates? Submit your updates here. ›

A highly structured abstract painting in soft blues, greens, and grays, featuring sweeping geometric arcs, concentric circular forms, and precise botanical spirals, conceptually representing the complex, interconnected nature of Synvitta's diagnostic technology.Synvitta's multiplex diagnostic platform aims to streamline workflows and improve precision in medical testing through advanced, interconnected systems.Alachua Today

Synvitta Diagnostics, an Alachua-based biotechnology startup, is positioning itself to reshape medical testing with its focus on multiplex diagnostic technology. The company has announced a new leadership partnership between co-founder and CEO Mitch Glaeser and co-founder and Chief Scientific Officer Rainara Almeida, combining business and scientific expertise. Synvitta is developing a platform that integrates rapid single-target tests and scalable multiplex systems, allowing laboratories to analyze multiple conditions simultaneously to streamline workflows, reduce processing time, and improve diagnostic accuracy.

Why it matters

Synvitta's approach to multiplex diagnostics has the potential to significantly improve healthcare by providing faster, more precise test results. This could lead to quicker diagnoses and treatment, especially for complex conditions. The company's goal of maintaining accessibility for healthcare providers is also crucial, as advanced diagnostic tools need to be widely available to have the greatest impact.

The details

Synvitta's platform is designed to integrate both rapid single-target tests and scalable multiplex systems, enabling laboratories to analyze multiple conditions at once. This approach is intended to streamline workflows, reduce processing time, and improve diagnostic accuracy in clinical settings. The company is initially focusing on applications for infectious diseases, autoimmune conditions, and neurodegenerative disorders, with plans to expand its diagnostic offerings in the future.

  • Synvitta Diagnostics was founded in Alachua, Florida.
  • The company announced its new leadership partnership in April 2026.

The players

Mitch Glaeser

Co-founder and Chief Executive Officer of Synvitta Diagnostics, Inc. Glaeser is also the founder of Alachua's San Felasco Tech City, a hub for emerging companies and collaborative research in biotechnology and sustainability.

Rainara Almeida

Co-founder and Chief Scientific Officer of Synvitta Diagnostics, Inc. Almeida brings scientific research expertise to the company's efforts to develop advanced diagnostic technology.

Synvitta Diagnostics, Inc.

A biotechnology startup based in Alachua, Florida, that is focused on advancing multiplex diagnostic testing to create faster, more efficient, and widely accessible diagnostic tools.

Got photos? Submit your photos here. ›

What they’re saying

“Synvitta represents a powerful combination of innovation and entrepreneurship. The ability to deliver multiplex diagnostics in a simple and scalable format creates a significant opportunity across multiple areas of healthcare.”

— Mitch Glaeser, Co-founder and Chief Executive Officer, Synvitta Diagnostics, Inc.

“Our mission is to make diagnostics more precise, faster, and accessible. We are building a platform that simplifies complex testing while maintaining high analytical performance, enabling better and faster clinical decision-making.”

— Rainara Almeida, Co-founder and Chief Scientific Officer, Synvitta Diagnostics, Inc.

What’s next

Synvitta is currently operating out of UF Innovate | Sid Martin Biotech, where it is advancing product development and working with clinical and strategic partners in the United States and abroad. The company plans to expand its diagnostic offerings to include applications for infectious diseases, autoimmune conditions, and neurodegenerative disorders.

The takeaway

Synvitta's multiplex diagnostic platform has the potential to revolutionize medical testing by providing faster, more precise, and more accessible diagnostic tools. This could lead to quicker diagnoses and improved patient outcomes, particularly for complex conditions. The company's focus on integrating its technology into existing laboratory systems without adding complexity is a key strategy for driving widespread adoption and making advanced diagnostics available to a broader range of healthcare providers.